Adial Pharmaceuticals, Inc. Financing Interest Expense
Adial Pharmaceuticals, Inc. (ADIL) reported Financing Interest Expense of $1.17 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-20.
Discontinued › Expense Statement › Interest Expense
us-gaap:FinancingInterestExpense · last filed 2020-03-20
- Adial Pharmaceuticals, Inc. financing interest expense for the quarter ending 2018-12-31 was $186.40K, a 126.77% increase year-over-year.
- Adial Pharmaceuticals, Inc. financing interest expense for the quarter ending 2018-09-30 was $878.08K, a 2806.59% increase year-over-year.
- Adial Pharmaceuticals, Inc. financing interest expense for the quarter ending 2018-06-30 was $50.89K.
- Adial Pharmaceuticals, Inc. financing interest expense for the quarter ending 2018-03-31 was $51.68K.
- Adial Pharmaceuticals, Inc. financing interest expense for fiscal 2018 was $1.17M, a 707.44% increase from fiscal 2017.
- Adial Pharmaceuticals, Inc. financing interest expense for fiscal 2017 was $144.54K.
| Period end | Financing Interest Expense 3 month | Financing Interest Expense 6 month | Financing Interest Expense 9 month | Financing Interest Expense 12 month |
|---|---|---|---|---|
| 2018-12-31 | $186.40K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | $1.06M derived: sum of 2 quarters · filed 2020-03-20 | $1.12M derived: sum of 3 quarters · filed 2020-03-20 | $1.17M 10-K · filed 2020-03-20 |
| 2018-09-30 | $878.08K 10-Q · filed 2019-11-14 | $928.97K derived: sum of 2 quarters · filed 2019-11-14 | $980.65K 10-Q · filed 2019-11-14 | $1.06M derived: sum of 4 quarters · filed 2019-11-14 |
| 2018-06-30 | $50.89K 10-Q · filed 2019-08-13 | $102.57K 10-Q · filed 2019-08-13 | $184.76K derived: sum of 3 quarters · filed 2019-08-13 | $214.97K derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $51.68K 10-Q · filed 2019-05-13 | $133.88K derived: sum of 2 quarters · filed 2019-05-13 | $164.09K derived: sum of 3 quarters · filed 2019-05-13 | |
| 2017-12-31 | $82.20K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $112.41K derived: sum of 2 quarters · filed 2019-02-19 | $144.54K 10-K · filed 2019-02-19 | |
| 2017-09-30 | $30.21K 10-Q · filed 2018-11-14 | $62.34K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |